The American Journal of Medicine
Volume 123, Issue 4 , Pages 322-328.e2 , April 2010

Long-acting Beta-Agonists with and without Inhaled Corticosteroids and Catastrophic Asthma Events

  • Shelley R. Salpeter, MD, FACP

      Affiliations

    • Stanford University School of Medicine, Stanford, Calif
    • Santa Clara Valley Medical Center, San Jose, Calif
    • Corresponding Author InformationReprint requests should be addressed to Shelley Salpeter, MD, 751 S. Bascom Ave, San Jose, CA 95128
    • ,
  • Andrew J. Wall, MD

      Affiliations

    • Stanford University School of Medicine, Stanford, Calif
    • Santa Clara Valley Medical Center, San Jose, Calif
    • ,
  • Nicholas S. Buckley

      Affiliations

    • California Institute for Technology, Pasadena

References 

  1. US Food and Drug Administration Office of Surveillance and Epidemiology. Risks and benefits of long-acting beta adrenergic agonists in the treatment of asthma. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4398b1-01-FDA.pdfAccessed December 6, 2008
  2. Kramer JM. Balancing the benefits and risks of inhaled long-acting beta-agonists–the influence of values. N Engl J Med. 2009;360:1592–1595
  3. Drazen JM, O'Byrne PM. Risks of long-acting beta-agonists in achieving asthma control. N Engl J Med. 2009;360:1671–1672
  4. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Long-acting beta-agonists increase severe asthma exacerbations and asthma-related deaths: meta-analysis of randomized controlled trials. Ann Intern Med. 2006;144:904–912
  5. Cates CJ, Cates MJ. Regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev. 2008;CD006363
  6. Cates CJ, Cates MJ, Lasserson TJ. Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev. 2008;(4):CD006923
  7. Sears MR, Ottosson A, Radner F, Suissa S. Long-acting beta-agonists: a review of formoterol safety data from asthma clinical trials. Eur Respir J. 2009;33:21–32
  8. Levenson M. Long-acting beta-agonists and adverse asthma events meta-analysis. Statistical briefing package for Joint Meeting of the Pulmonary-Allergy Drugs Advisory Committee, Drug Safety and Risk Management Advisory Committee and Pediatric Advisory Committee on December 10-11, 2008 http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4398b-01-FDA.pdfAccessed December 6, 2008
  9. GlaxoSmithKline. Sponsor briefing information (Benefit risk assessment of salmeterol for the treatment of asthma in adults and children). http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4398b1-04-GSK.pdfAccessed December 6, 2008
  10. Novartis. Foradil. FDA Advisory Committee meeting on the safety of long-acting beta2-agonists for the treatment of asthma in adults and children (December 10-11, 2008). Briefing document http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4398b1-02-Novartis.pdfAccessed December 6, 2008
  11. AstraZeneca. AstraZeneca briefing materials: Review of the benefits and risks of formoterol-containing products. http://www/fda.gov/ohrms/dockets/ac/08/briefing/2008-4398b1-03-AstraZeneca.pdfAccessed December 6, 2008
  12. Jaeschke R, O'Byrne PM, Mejza F, et al. The safety of long-acting beta-agonists among patients with asthma using inhaled corticosteroids: systematic review and metaanalysis. Am J Respir Crit Care Med. 2008;178:1009–1016
  13. Jaeschke R, O'Byrne PM, Nair P, et al. The safety of formoterol among patients with asthma using inhaled corticosteroids (Systematic review and meta-analysis). Pol Arch Med Wewn. 2008;118:627–635
  14. Bateman E, Nelson H, Bousquet J, et al. Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. Ann Intern Med. 2008;149:33–42
  15. Rodrigo GJ, Moral VP, Marcos LG, Castro-Rodriguez JA. Safety of regular use of long-acting beta agonists as monotherapy or added to inhaled corticosteroids in asthma (A systematic review). Pulm Pharmacol Ther. 2009;22:9–19
  16. US Food and Drug Administration. Summary minutes of the joint Pulmonary-Allergy Drugs Advisory Committee, Drug Safety and Risk Management Advisory Committee, and Pediatric Advisory Committee, December 10-11, 2008. http://www.fda.gov/ohrms/dockets/AC/08/minutes/2008-4398m1-final.pdfAccessed February 6, 2009
  17. Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med. 2007;26:53–77
  18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188
  19. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ. 2003;326:219
  20. U.S Food and Drug Association. Center for Drug Evaluation and Review. Foradil (Formoterol Fumarate inhalation) aerolizer. Part 4 http://www.fda.gov/cder/foi/nda/2001/20831_Foradil_medr_P4.pdfAccessed September 3, 2005
  21. U.S Food and Drug Association. Center for Drug Evaluation and Review. Foradil (Formoterol Fumarate inhalation) aerolizer. Part 5 http://www.fda.gov/cder/foi/nda/2001/20831_Foradil_medr_P5.pdfAccessed September 3, 2005
  22. Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129:15–26
  23. Ind PW, Dal Negro R, Colman NC, et al. Addition of salmeterol to fluticasone propionate treatment in moderate-to-severe asthma. Respir Med. 2003;97:555–562
  24. Kelsen SG, Church NL, Gillman SA, et al. Salmeterol added to inhaled corticosteroid therapy is superior to doubling the dose of inhaled corticosteroids: a randomized clinical trial. J Asthma. 1999;36:703–715
  25. Kemp JP, Cook DA, Incaudo GA, et al. Salmeterol improves quality of life in patients with asthma requiring inhaled corticosteroids (Salmeterol Quality of Life Study Group). J Allergy Clin Immunol. 1998;101(2 Pt 1):188–195
  26. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med. 2001;164(8 Pt 1):1392–1397
  27. O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med. 2005;171:129–136
  28. Von Berg A, Papageorgiou Saxoni F, Wille S, et al. Efficacy and tolerability of formoterol Turbuhaler in children. Int J Clin Pract. 2003;57:852–856
  29. U.S Food and Drug Administration. NDA 020831 Formoterol fumarate clinical review. http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4148B1_03_03-FDA-Clinical-Review.pdfAccessed September 3, 2005
  30. Patterns of medication use in the United States, 2006. A Report from the Slone Survey. http://www.bu.edu/slone/SloneSurvey/AnnualRpt/SloneSurveyWebReport2006.pdfAccessed February 21, 2009
  31. Salpeter SR, Ormiston TM, Salpeter EE. Meta-analysis: respiratory tolerance to regular beta2-agonist use in patients with asthma. Ann Intern Med. 2004;140:802–813
  32. Lipworth BJ. Long-acting beta(2)-adrenoceptor agonists: a smart choice for asthma?. Trends Pharmacol Sci. 2007;28:257–262Epub 2007 Apr 26
  33. Sears MR, Taylor DR, Print CG, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet. 1990;336:1391–1396
  34. Kalra S, Swystun VA, Bhagat R, Cockcroft DW. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol. Chest. 1996;109:953–956
  35. Spitzer WO, Suissa S, Ernst P, et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med. 1992;326:501–506
  36. Kerrebijn KF, van Essen-Zandviet EEM, Neijens JJ. Effects of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthma. J Allergy Clin Immunol. 1987;79:653–659
  37. Suissa S, Ernst P. Inhaled corticosteroids: impact on asthma morbidity and mortality. J Allergy Clin Immunol. 2001;107:937–944
  38. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol. 2007;120(5 Suppl):S94–S138
  39. Gross NJ. Anticholinergic agents in asthma and COPD. Eur J Pharmacol. 2006;533:36–39
  40. Currie GP, Lee DK, Srivastava P. Long-acting bronchodilator or leukotriene modifier as add-on therapy to inhaled corticosteroids in persistent asthma?. Chest. 2005;128:2954–2962
  41. Kanazawa H. Anticholinergic agents in asthma: chronic bronchodilator therapy, relief of acute severe asthma, reduction of chronic viral inflammation and prevention of airway remodeling. Curr Opin Pulm Med. 2006;12:60–67
  42. Salpeter SR, Buckley NS. Author's response: Asthma-related death rate http://www.annals.org/cgi/eletters/144/12/904#3689Accessed February 22, 2009
  43. Wijesinghe M, Perrin K, Harwood M, et al. The risk of asthma mortality with inhaled long acting beta-agonists. Postgrad Med J. 2008;84:467–472

 Funding: Santa Clara Valley Medical Center, San Jose, Calif.

 Conflict of Interest: None of the authors have any conflicts of interest associated with the work presented in this manuscript. None of the authors have had any relationships with a pharmaceutical company that manufactures a β-agonist or other respiratory medications. Dr Salpeter has provided expert testimony on a litigation case involving a long-acting β-agonist and was paid on an hourly basis.

 Authorship: All authors had access to the data and played a role in writing this manuscript.

PII: S0002-9343(09)01110-3

doi: 10.1016/j.amjmed.2009.07.035

The American Journal of Medicine
Volume 123, Issue 4 , Pages 322-328.e2 , April 2010

Article Tools

* Image Usage & Resolution